<DOC>
	<DOCNO>NCT01350115</DOCNO>
	<brief_summary>This phase II , double-blind , randomize , proof-of-concept , dose-ranging trial evaluate efficacy , safety pharmacokinetics oral LDE225 treatment adult patient NBCCS . This exploratory study design demonstrate preliminary efficacy LDE225 indication . This study include Screening period approximately 4 week , treatment period duration 12 week initial follow-up approximately 6-8 week follow long-term follow-up period .</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics Oral LDE225 Treatment Patients With Nevoid Basal Cell Carcinoma Syndrome ( NBCCS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<criteria>Patients multiple basal cell carcinoma ( least two ) typical presentation NBCCS . Female patient must woman nonchildbearing potential ( WONCBP ) . Use topical treatment treat BCCs , include prescription counter 4 week prior first dose study drug . Use photodynamic therapy ( PDT ) , radiation systemic treatment know affect BCCs neoplasm 12 week prior first dose study drug . Patients receive medication recognize cause rhabdomyolysis patient prior history rhabdomyolysis . Patients histologically confirm diagnosis locally advance metastatic BCC . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Basal Cell Carcinoma</keyword>
	<keyword>Gorlin Syndrome ,</keyword>
	<keyword>Gorlin-Goltz Syndrome ,</keyword>
	<keyword>Basal Cell Nevus Syndrome ,</keyword>
	<keyword>Nevoid Basal Cell Carcinoma Syndrome ,</keyword>
	<keyword>Basal Cell Carcinoma Nevus Syndrome</keyword>
	<keyword>Smo inhibitor ,</keyword>
	<keyword>Hedgehog pathway inhibitor</keyword>
	<keyword>BCCs</keyword>
</DOC>